Patent application number | Description | Published |
20100131059 | INTRAOCULAR LENS OPTIC - An intraocular lens optic (e.g. FIG. | 05-27-2010 |
20100228260 | INJECTOR FOR INTRAOCULAR LENS - The invention is directed to an injector assembly and method of using the injector assembly that is part of a package in which the lens is sterilized and shipped together with the injector. The assembly comprises an injector barrel which has a circular end and a tapered end, an intraocular lens, and a haptic within the barrel. The assembly is comprised of a material that is packaged and sterilized as a single unit. | 09-09-2010 |
20110191086 | MODEL OF ACCOMMODATIVE INTRAOCULAR LENS - The invention is directed to a model comprising a diagrammatical and geometric simplification of the components of the natural eye whose functionality is fundamental to the successful performance of a pseudo-aphakic accommodative lens. This model allows for a functional correlation of each component of the ophthalmic device with the patient needs. The eye model was developed to show the movement of the eye from the distance vision to the near vision positions through multiple phases of accommodative motion. The inventive model was developed using a mathematical series of formulas to calculate each of the components of focal accommodation in a human eye, quantify these, and construct the pictorial ramifications of such calculations. The inventive model presents an analysis of accommodative dynamics in the human eye with the natural lens in place. The inventive model also demonstrates the accommodative dynamics with a proprietary IOL in place of the natural lens and situated within the lens capsule. | 08-04-2011 |
20110313522 | Pseudophakic Accommodating Intraocular Lens - The invention is directed to an assembly comprising a haptic for fixation to, and manufacture in conjunction with, an intraocular lens to be implanted in the natural lens capsule of an eye. The haptic of the invention comprises a continuous ribbon forming an essentially oblong shape having anterior and posterior portions relative to the elliptical center of the haptic, wherein the ribbon loop includes two or more essentially congruent ribbon arches in each portion, and each ribbon arch has a natural index of curvature with an inner and outer edges. designed to expand the eye capsule and put tension on the zonules of the eye. The ribbon affixes to the lens on each side of the optic edge at a point or a series of points that provides suitable centration and stability of the optic, and to suspend the optic in the open capsular space. The material of the haptic is preferably somewhat flexible, and elastic, so as to provide a constant, positive force on the capsule throughout all phases of accommodation, thereby preserving tension of the zonules and allowing the capsule to change shape naturally. The haptic ribbons may be solid or of an open work structure to increase the amount of hydration available to the lens capsule. A secondary haptic ribbon, affixed to a plano optical plate, may be located on the posterior capsular surface and oriented so that the haptic arms extend through the capsular prime meridian to the anterior capsular surface at a 90° angle from the anterior haptic ribbons, thus providing for a capsular configuration as natural as possible, yet associated with an intraocular lens that may be inserted through an incision of less than 3 millimeters. | 12-22-2011 |
20110313523 | Pseudophakic Accommodating Intraocular Lens - The invention is directed to an assembly comprising a haptic for fixation to, and manufacture in conjunction with, an intraocular lens to be implanted in the natural lens capsule of an eye. The haptic of the invention comprises a continuous ribbon forming an essentially oblong shape having anterior and posterior portions relative to the elliptical center of the haptic, wherein the ribbon loop includes two or more essentially congruent ribbon arches in each portion, and each ribbon arch has a natural index of curvature with an inner and outer edges. designed to expand the eye capsule and put tension on the zonules of the eye. The ribbon affixes to the lens on each side of the optic edge at a point or a series of points that provides suitable centration and stability of the optic, and to suspend the optic in the open capsular space. The material of the haptic is preferably somewhat flexible, and elastic, so as to provide a constant, positive force on the capsule throughout all phases of accommodation, thereby preserving tension of the zonules and allowing the capsule to change shape naturally. The haptic ribbons may be solid or of an open work structure to increase the amount of hydration available to the lens capsule. A secondary haptic ribbon, affixed to a plano optical plate, may be located on the posterior capsular surface and oriented so that the haptic arms extend through the capsular prime meridian to the anterior capsular surface at a 90° angle from the anterior haptic ribbons, thus providing for a capsular configuration as natural as possible, yet associated with an intraocular lens that may be inserted through an incision of less than 3 millimeters. | 12-22-2011 |
20120303119 | CAPSULAR OPACIFICATION BLOCKING LENS - The invention is directed to a lens that comprises an optic and two haptic rings, one positioned to rest against the posterior capsule distally outward from the optic zone, the other to rest on the anterior capsule some distance from the equator. The haptic rings of the lens are connected by segments of haptic material that may be arched or straight, and sections of open space to provide for ample circulation of the aqueous humor. The optic is positioned against the posterior capsule as close as possible to the nodal zone of the eye. | 11-29-2012 |
20120330415 | HAPTIC DEVICES FOR INTRAOCULAR LENS - A haptic for fixation to, and manufacture in conjunction with, an intraocular lens to be implanted in the natural lens capsule of the human eye is disclosed. The haptic secures the lens in an appropriate position within the natural capsule so as to provide optimal visual acuity through the aphakic lens. The haptic ends are designed to position the lens neutrally, anteriorly or posteriorly within the lens envelope. The haptic has a of an anterior retention ring and a posterior retention ring. | 12-27-2012 |
20130184816 | INTRAOCULAR LENS RINGS - The invention is directed to a lens that comprises an optic and at least two haptic rings, one positioned to rest against the posterior capsule distally outward from the optic zone, the other to rest on the anterior capsule some distance from the equator. The haptic rings of the lens are connected by segments of haptic material that may be arched or straight, and sections of open space to provide for ample circulation of the aqueous humor. The optic is suspended between the two haptic rings such that the distance between the optic and the anterior ring is constant while the distance between the optic and the posterior ring may vary according to the overall capsular dimensions of the eye of the patient. | 07-18-2013 |
20150327991 | HAPTIC DEVICES FOR INTRAOCULAR LENS - A haptic for fixation to, and manufacture in conjunction with, an intraocular lens to be implanted in the natural lens capsule of the human eye is disclosed. The haptic secures the lens in an appropriate position within the natural capsule so as to provide optimal visual acuity through the aphakic lens. The haptic is designed to position the lens neutrally, anteriorly or posteriorly within the lens envelope. The haptic has an anterior retention ring and a posterior retention ring. | 11-19-2015 |
Patent application number | Description | Published |
20110104326 | BALANCED SN-2 MYRISTATE-CONTAINING EDIBLE OIL - A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma is described. The composition typically includes at least 1% by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1:1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. | 05-05-2011 |
20110166227 | BALANCED MYRISTATE- AND LAURATE-CONTAINING EDIBLE OIL - Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol. | 07-07-2011 |
20110229600 | SN-2 MYRISTATE-CONTAINING EDIBLE OIL - A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma is described. The composition can advantageously include at least 1% by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1:1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. | 09-22-2011 |
20110305791 | METHOD AND COMPOSITION FOR NUTRITIONALLY IMPROVING GLUCOSE CONTROL AND INSULIN ACTION - Disclosed is a method and composition for nutritionally improving glucose and insulin balance in an individual. The invention further provides a method for treating a comorbidity of diabetes. In one embodiment, the invention provides a nutritional formulation comprising: a protein source; a fat source; and a carbohydrate source, wherein the protein source, the fat source, and the carbohydrate source are in a ratio of about 1:1:1, each comprising about one third of the total calories of the composition. | 12-15-2011 |
20120282368 | AMPHIPHILIC STEROL/FAT-BASED PARTICLES - The present invention relates to amphiphilic sterol- and fat-based particles, which can be dispersed in liquid foods and beverages such as milk. The compositions provided, when consumed, reduce low-density lipoprotein (LDL) and total plasma cholesterol (TC) levels. | 11-08-2012 |
20130053442 | BALANCED MYRISTATE- AND LAURATE-CONTAINING EDIBLE OIL - Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol. | 02-28-2013 |
20130260003 | BALANCED MYRISTATE-AND LAURATE-CONTAINING EDIBLE OIL - Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol. | 10-03-2013 |
20140127349 | VEGETABLE OIL COMPOSITION CONTAINING PALM MID-FRACTION FAT AND METHOD OF REDUCING PLASMA CHOLESTEROL - A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position. | 05-08-2014 |
20140127386 | VEGETABLE OIL COMPOSITION CONTAINING PALM MID-FRACTION FAT AND METHOD OF REDUCING PLASMA CHOLESTEROL - A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position. | 05-08-2014 |
20150079226 | VEGETABLE OIL COMPOSITION CONTAINING PALM MID-FRACTION FAT AND METHOD OF REDUCING PLASMA CHOLESTEROL - A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position. | 03-19-2015 |